ANTEOTECH LTD — Interim / Quarterly Report 2012

Apr 29, 2012

==> picture [209 x 115] intentionally omitted <==

30 April 2012 Company Announcements Office Australian Stock Exchange Level 6, 20 Bridge Street Sydney NSW 2000

Appendix 4C for the quarter ending 31 March 2012 (ASX:ADO) Anteo Diagnostics Limited (ASX : ADO) attaches its Appendix 4C for the quarter ending 31 March 2012.

CEO REPORT - QUARTER ENDED 31 MARCH 2012

Dear Shareholders,

Anteo Diagnostics Limited (ASX:ADO) is pleased to report on its activities for the quarter ending 31 March 2012. This quarter had the following highlights:

• The execution of a Patent and Technology License Agreement with eBioscience

• Ongoing development and recognition of our patent portfolio

• Presentation of a poster at the AACC Oak Ridge conference and ongoing customer development;

• Further development of blockers and quenching agents for Mix&Go™ to provide a total solution for customers.

• Acceleration of our efforts into the creation of “demonstration data” that exemplifies the benefits of Mix&Go on ceramic surfaces, silica, plastic plates and other plastic materials commonly used in life sciences research.

eBIOSCIENCE

On 13[th] March Anteo announced that it had signed a Patent and Technology License Agreement with eBioscience. eBioscience Inc is a US based organisation with sales revenues approaching $100M that has been enjoying double digit growth for the past 5 years. They are a world leader in the manufacture and marketing of immunology and oncology flow cytometry reagents. One of their current key product ranges is FlowCytomix – a bead based immunoassay system for use on flow cytometers. FlowCytomix kits allow for the simultaneous analysis of up to 20 proteins in a single reaction. eBioscience is currently working to incorporate Mix&Go™ into their FlowCytomix range. The logistics surrounding these changes are jointly being addressed at present.

Anteo Diagnostics Limited ABN 78 090 487 273 Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113 Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

==> picture [209 x 115] intentionally omitted <==

eBioscience recognises that there are numerous other applications for Mix&Go™ both within their existing product range and with new products that are under development. Anteo is committed to providing whatever assistance is possible to ensure incorporation of Mix&Go™ into these products at the earliest possible opportunity.

PATENT PORTFOLIO

In March it was announced that Anteo had filed a divisional patent on the “Use of Metal Complexes” patent and that the parent patent was likely to be granted imminently. No official notification of this grant has been received as yet.

The intent of this patent approach was to enhance our flexibility with respect to discussions with prospective licensees.

AACC OAK RIDGE CONFERENCE AND CUSTOMER DEVELOPMENT

Anteo submitted a poster that was accepted for presentation at the Oak Ridge Conference – Emerging Technologies for 21[st] Century Clinical Diagnostics in April. More regular attendance at conferences, like Oak Ridge, forms an important part of our marketing and business development activities, enabling us to directly interact with both current and new parties with whom we would like to be dealing. A range of discussions from introduction to the technology to commercial negotiations were progressed through the course of the conference. In addition, several other companies who have used Mix&Go™ but were unable to attend the conference were visited to progress interactions.

PROVIDING CUSTOMERS WITH A TOTAL SOLUTION

Mix&Go™ provides users with the ability to develop highly sensitive tests capable of measuring into the femtogram/ml range (10[-18] g/ml). As a new approach that enables users to deal with such small amounts of material, it is critical that only measurements of the analyte (object) of interest are made ie there are no non-specific measurements. Our scientists are devoting considerable time to minimising non-specific effects with a view to further enhancing the value of our products by providing a complete solution centered on Mix&Go™. Several “blockers” have been developed specifically for use with Mix&Go™. Through this approach we believe that we can offer a total solution to companies developing highly sensitive tests on a range of different surfaces.

USE OF MIX&GO ON OTHER SURFACES

Most of the work undertaken to date with Mix&Go™ has been done on polystyrene beads. Whilst these surfaces are commonly used in biological settings, there a number of other surfaces that are also used. Our scientists have been testing and modifying Mix&Go™ to suit these different surfaces. In this manner we intend to be able to provide a solution to customers no matter what their surface of choice.

Anteo Diagnostics Limited ABN 78 090 487 273 Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113 Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

==> picture [209 x 115] intentionally omitted <==

CORPORATE

Anteo’s cash balance was slightly up on last quarter with $5,619,723 in the bank on 31 March 2012. This gives Anteo further confidence that it can fund its activities past the end of 2013 at the current burn rate. This forecast excludes any future potential revenue streams.

We are pleased with the progress Anteo is making and we are focused on converting enquiries into new sales and licensing agreements. We are excited by the Mix&Go™ technology and the Board has sound reasons for continued optimism.

Dr Geoff Cumming CEO Anteo Diagnostics Limited

Anteo Diagnostics Limited ABN 78 090 487 273 Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113 Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com

Rule 4.7B

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Name of entity Anteo Diagnostics Limited ACN or ARBN Quarter ended (“currentquarter”)	Name of entity Anteo Diagnostics Limited ACN or ARBN Quarter ended (“currentquarter”)
75-070-028-625	31-Mar-12

Consolidated statement of cash flows

Consolidated statement of cash flows
Cash flows related to operating activities	Current quarter $A’000	Year to date (9 months) $A’000
1.2 Payments for (a) staff costs (b) advertising and marketing (c) research and development (excluding staff costs relating to R&D) (d) leased assets (e) other working capital 1.3 Dividends received 1.4 Interest and other items of a similar nature received 1.5 Interest and other costs of finance paid 1.6 Income taxes paid 1.1 Receipts from customers and government grants	972 (469) (120) (98) - (304) - 73 (2) -	1,059 (1,184) (266) (344) - (828) - 339 (2) -
Net operating cash flows	52	(1,226)

NOTES:

		Current quarter $A’000	Year to date (9 months) $A’000
1.8	Net operating cash flows (carried forward)	52	(1,226)
1.9 1.11 1.12 1.13 1.10	Cash flows related to investing activities Payment for acquisition of: (a) Businesses (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets Proceeds from disposal of: (a) Businesses (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets Loans to other entities Loans repaid by other entities Adjustment for cash remaining in subsidiary entity at disposal Net investing cash flows	- - - (15) - - - - - - - - -	- - - (72) - - - - - - - - -
		(15)	(72)
1.14	Total operating and investing cash flows
		37	(1,298)
1.15 1.16 1.17 1.18 1.19 1.20	Cash flows related to financing activities Proceeds from issues of shares, options, etc. Proceeds from sale of forfeited shares Proceeds from borrowings Repayment of borrowings Dividends paid Other: Conversion of converting notes Interest paid on converting notes Capital raising costs Net financing cash flows	54 - - - - - - -	54 - - - - - - -
		54	54
1.21 1.22 1.23	Net increase (decrease) in cash held Cash at beginning of quarter/year to date Exchange rate adjustments to item 1.20 Cash at end ofquarter
		91 5,529 -	(1,244) 6,864 -
		**5,620 **	5,620
NOTES: 1.20

Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities

1.24 Aggregate amount of payments to the parties included in item 1.2 1.25 Aggregate amount of loans to the parties included in item 1.11	1.24 Aggregate amount of payments to the parties included in item 1.2 1.25 Aggregate amount of loans to the parties included in item 1.11	Current quarter $A'000
		182
		NIL
1.26 Explanation necessary for an understanding of the transactions

Non-cash financing and investing activities

• 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

NIL

• 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

NIL

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

3.1 Loan facilities 3.2 Credit standby arrangements	Amount available $A’000	Amount used $A’000
	NIL	NIL
	NIL	NIL

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter $A’000	Previous quarter $A’000
4.1 Cash on hand and at bank 4.2 Deposits at call 4.3 Bank overdraft 4.4 Other-Funds held in trust re. Open Prospectus Offer	5,492	5,036
	128	493
		-
		-
Total: cash at end of quarter(item 1.23)	5,620	5,529

Acquisitions and disposals of business entities

Acquisitions and disposals of business entities
5.1 Acquisition/disposal of subsidiary 5.2 Place of incorporation or registration 5.3 Consideration for acquisition or disposal 5.4 Total net assets at date of acquisition/disposal Nature of business 5.5	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))

Compliance statement

1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act 2001 (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement [does] give a true and fair view of the matters disclosed.

Sign here:

==> picture [112 x 36] intentionally omitted <==

Date: 30 April 2012

(Director)

Print name: Richard Martin